Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05422690 · ClinicalTrials.gov registry record · Phase 2
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
A Phase 2 study of Intrahepatic Cholangiocarcinoma, sponsored by Inova Health Care Services.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05422690 is a Phase 2 study of Intrahepatic Cholangiocarcinoma that is actively recruiting participants, run by Inova Health Care Services. The registered enrollment target is 16 participants, below the 135-participant average among 17 other Intrahepatic Cholangiocarcinoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05422690, a Phase 2 study of Intrahepatic Cholangiocarcinoma, is actively recruiting participants, sponsored by Inova Health Care Services.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to see if combining gemcitabine, cisplatin and Durvalumab chemotherapy treatments with a direct tumor therapy called Yittrium-90, will work better together to shrink the tumor and control cancer.
Conditions Studied
Interventions
- DRUG Induction Chemotherapy Triplet Therapy
- RADIATION Concurrent Y-90 treatment
- DRUG Consolidation Doublet Therapy:
Study Locations (1)
Virginia
- Keary Janet - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-06-12 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05422690
The ClinicalTrials.gov registry entry for NCT05422690 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 17 other Intrahepatic Cholangiocarcinoma trials with a reported enrollment target (88% lower). The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intrahepatic Cholangiocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Induction Chemotherapy Triplet Therapy is the first listed.
NCT05422690 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT05422690 about?
NCT05422690 is a clinical study titled "The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer". The purpose of this research is to see if combining gemcitabine, cisplatin and Durvalumab chemotherapy treatments with a direct tumor therapy called Yittrium-90, will work better together to shrink the tumor and control cancer.
What is the current status of trial NCT05422690?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2024-06-12. Estimated completion is 2028-09-30.
What conditions does trial NCT05422690 study?
This clinical trial studies the following conditions: Intrahepatic Cholangiocarcinoma.
What interventions are being tested in trial NCT05422690?
The interventions under investigation include: Induction Chemotherapy Triplet Therapy (DRUG), Concurrent Y-90 treatment (RADIATION), Consolidation Doublet Therapy: (DRUG).
Who is sponsoring clinical trial NCT05422690?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05422690 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intrahepatic Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
RECRUITING · Phase 2
-
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
RECRUITING · Phase 2
-
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
RECRUITING · Phase 2
-
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
RECRUITING · Phase 2
-
Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
RECRUITING · Phase 2
-
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.